Non-functioning pituitary adenoma
disease diseaseOn this page
Also known as functionless adenoma of pituitaryfunctionless adenoma of pituitary glandfunctionless adenoma of the pituitaryfunctionless adenoma of the pituitary glandfunctionless pituitary adenomafunctionless pituitary gland adenomaNFPAnon-functioning adenoma of pituitarynon-functioning adenoma of pituitary glandnon-functioning adenoma of the pituitarynon-functioning adenoma of the pituitary glandnon-functioning pituitary gland adenomanon-secretory adenoma of pituitarynon-secretory adenoma of pituitary glandnon-secretory adenoma of the pituitarynon-secretory adenoma of the pituitary glandnon-secretory pituitary adenomanon-secretory pituitary gland adenomanonfunctional pituitary gland adenoma
Summary
Non-functioning pituitary adenoma (MONDO:0019613) is a cancer and 5 clinical trials. Top therapeutic interventions include cabergoline, pasireotide, and sodium chloride. A subtype of non-functioning pituitary gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 58
- Clinical trials: 5
Clinical features
Epidemiology
Prevalence records
9 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 1.05 | Worldwide | Validated |
| Point prevalence | 1-5 / 10 000 | Europe | Validated | |
| Annual incidence | 1-9 / 100 000 | 4 | Finland | Validated |
| Annual incidence | 1-9 / 100 000 | 1.1 | Sweden | Validated |
| Point prevalence | 6-9 / 10 000 | 94 | Belgium | Validated |
| Point prevalence | 6-9 / 10 000 | 80.5 | Switzerland | Validated |
| Point prevalence | 6-9 / 10 000 | 77.6 | United Kingdom | Validated |
| Point prevalence | 6-9 / 10 000 | 68 | Finland | Validated |
| Annual incidence | 1-9 / 100 000 | 2.55 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
58 HPO clinical features (Orphanet curated; top 50 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002893 | Pituitary adenoma | Very frequent (80-99%) |
| HP:0000026 | Male hypogonadism | Frequent (30-79%) |
| HP:0000044 | Hypogonadotropic hypogonadism | Frequent (30-79%) |
| HP:0000134 | Female hypogonadism | Frequent (30-79%) |
| HP:0000135 | Hypogonadism | Frequent (30-79%) |
| HP:0000140 | Abnormality of the menstrual cycle | Frequent (30-79%) |
| HP:0000529 | Progressive visual loss | Frequent (30-79%) |
| HP:0000802 | Impotence | Frequent (30-79%) |
| HP:0000824 | Decreased response to growth hormone stimulation test | Frequent (30-79%) |
| HP:0000830 | Anterior hypopituitarism | Frequent (30-79%) |
| HP:0000837 | Increased circulating gonadotropin level | Frequent (30-79%) |
| HP:0000846 | Adrenal insufficiency | Frequent (30-79%) |
| HP:0000858 | Irregular menstruation | Frequent (30-79%) |
| HP:0000868 | Decreased fertility in females | Frequent (30-79%) |
| HP:0000980 | Pallor | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002017 | Nausea and vomiting | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002615 | Hypotension | Frequent (30-79%) |
| HP:0002920 | Decreased circulating ACTH level | Frequent (30-79%) |
| HP:0003388 | Easy fatigability | Frequent (30-79%) |
| HP:0008240 | Secondary growth hormone deficiency | Frequent (30-79%) |
| HP:0008245 | Pituitary hypothyroidism | Frequent (30-79%) |
| HP:0008993 | Increased intraabdominal fat | Frequent (30-79%) |
| HP:0010972 | Anemia of inadequate production | Frequent (30-79%) |
| HP:0011362 | Abnormal hair quantity | Frequent (30-79%) |
| HP:0011734 | Central adrenal insufficiency | Frequent (30-79%) |
| HP:0011735 | Adrenocorticotropin deficient adrenal insufficiency | Frequent (30-79%) |
| HP:0011748 | Adrenocorticotropic hormone deficiency | Frequent (30-79%) |
| HP:0011804 | Abnormal muscle physiology | Frequent (30-79%) |
| HP:0012041 | Decreased fertility in males | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0012503 | Abnormality of the pituitary gland | Frequent (30-79%) |
| HP:0030018 | Decreased female libido | Frequent (30-79%) |
| HP:0030521 | Bitemporal hemianopia | Frequent (30-79%) |
| HP:0040075 | Hypopituitarism | Frequent (30-79%) |
| HP:0100639 | Erectile dysfunction | Frequent (30-79%) |
| HP:0000508 | Ptosis | Occasional (5-29%) |
| HP:0000618 | Blindness | Occasional (5-29%) |
| HP:0000651 | Diplopia | Occasional (5-29%) |
| HP:0000863 | Central diabetes insipidus | Occasional (5-29%) |
| HP:0000870 | Increased circulating prolactin concentration | Occasional (5-29%) |
| HP:0000871 | Panhypopituitarism | Occasional (5-29%) |
| HP:0000873 | Diabetes insipidus | Occasional (5-29%) |
| HP:0001117 | Sudden loss of visual acuity | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0002050 | Macroorchidism, postpubertal | Occasional (5-29%) |
| HP:0002321 | Vertigo | Occasional (5-29%) |
| HP:0006824 | Cranial nerve paralysis | Occasional (5-29%) |
| HP:0006897 | Abducens palsy | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | non-functioning pituitary adenoma |
| Mondo ID | MONDO:0019613 |
| EFO | EFO:0008516 |
| Orphanet | 91349 |
| DOID | DOID:5715 |
| ICD-11 | 1197752358 |
| NCIT | C4348 |
| SNOMED CT | 254962005 |
| GARD | 0019159 |
| Anatomy (UBERON) | UBERON:0000007 |
| Is cancer (heuristic) | yes |
Also known as: functionless adenoma of pituitary · functionless adenoma of pituitary gland · functionless adenoma of the pituitary · functionless adenoma of the pituitary gland · functionless pituitary adenoma · functionless pituitary gland adenoma · NFPA · non-functioning adenoma of pituitary · non-functioning adenoma of pituitary gland · non-functioning adenoma of the pituitary · non-functioning adenoma of the pituitary gland · non-functioning pituitary adenoma · non-functioning pituitary gland adenoma · non-secretory adenoma of pituitary · non-secretory adenoma of pituitary gland · non-secretory adenoma of the pituitary · non-secretory adenoma of the pituitary gland · non-secretory pituitary adenoma · non-secretory pituitary gland adenoma · nonfunctional pituitary gland adenoma (+1 more)
Data availability: 1 cell line.
Disease family
This is a subtype of non-functioning pituitary gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › pituitary tumor › non-functioning pituitary gland neoplasm › non-functioning pituitary adenoma
Subtypes (2): silent pituitary adenoma, null pituitary adenoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01620138 | PHASE2/PHASE3 | COMPLETED | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas |
| NCT01283542 | PHASE2 | COMPLETED | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. |
| NCT05005715 | PHASE2 | UNKNOWN | Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery |
| NCT06163261 | Not specified | RECRUITING | Individualized Physical Activity or Patients With Non Functioning Pituitary Adenoma |
| NCT04218721 | Not specified | COMPLETED | Implementing eHealth Interventions Into Regular Clinical Practice |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABERGOLINE | 4 | 1 |
| PASIREOTIDE | 4 | 1 |
| SODIUM CHLORIDE | 4 | 1 |
| CHEMBL4593105 | 0 | 1 |
| CHEMBL5192470 | 0 | 1 |
Related Atlas pages
- Drugs: Cabergoline, Pasireotide, Sodium Chloride